TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Valve Medical's Xemed TAVR valve

Cardiologists perform world’s first TAVR with new ultra-low profile valve

The 88-year-old patient was originally not seen as a viable candidate for TAVR or surgery.

The Wattson temporary pacing guidewire from Teleflex

FDA clears new guidewire used for valve delivery and ventricular pacing during TAVR, BAV procedures

The device, now on display at TVT 2023 in Phoenix, is scheduled to begin hitting the market in the months ahead. 

Antithrombotic therapy after TAVR: Comparing warfarin to DAPT, SAPT

A new retrospective study from the Mayo Clinic focused on patients with no other need for anticoagulation.

EnCompass Technologies F2 embolic filter device TAVR embolic device

Interventional cardiologists perform world’s first TAVR with new embolic protection device

The device, designed with improved filtration and stability in mind, is now being investigated as part of a new pilot study. 

Thumbnail

TAVR controversy: Surgeon fired after saying cardiologist treated patients without proper credentials

An Ohio doctor allegedly performed multiple procedures without the proper credentials. A vascular surgeon is now out of work for sharing the story with a local media outlet. 

Thumbnail

TAVR among 90-year-old patients: An updated look at mortality, hospital costs and more

In-hospital mortality and other key outcomes have improved in recent years, but treating these older patients is still associated with certain challenges. 

The DurAVR transcatheter heart valve (THV), developed by Minnesota-based Anteris Technologies

New biomimetic TAVR valve, the first of its kind, linked to strong performance after 1 year

The DurAVR transcatheter heart valve, developed by Minnesota-based Anteris Technologies, was designed to move and perform like a healthy, pre-disease native aortic valve.

Abbott TriClip device for TEER

EuroPCR 2023: Late-breaking research examines the latest in TEER, TAVR and PCI outcomes

Catch up on key late-breaking research from Abbott, Edwards Lifesciences and Philips presented at the four-day meeting in Paris.